Acalabrutinib in CNSL

Clinical trial NCT04906902 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04906902
Sponsor: Dana-Farber Cancer Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Central Nervous System Lymphoma Refractory Central Nervous System Lymphoma Recurrent Central Nervous System Lymphoma

Start date: 2021-08-23
Primary completion: 2025-11-06
Enrollment: 49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.